Proud to share that Part the Cloud is investing nearly $7 million in 5 promising Alzheimer's therapies to help move them into clinical trials — combination strategies, a repurposed diuretic and our first AI-designed antibody therapy. Learn more: bit.ly/4ruxb02

Alzheimer's Association Part the Cloud Grants $7 Million to Accelerate Visionary Treatment Candidates into Clinical Trials

Funding aims to accelerate visionary Alzheimer's and dementia treatment candidates into clinical trials. To date, Part the Cloud has funded 88 trials across the globe.

bit.ly

4 FDA-cleared blood tests for Alzheimer's diagnosis & 2 cleared within a few days of each other. It's the kind of progress we've been working toward for decades. This is the research community doing what it does best: turning ideas and discovery into real tools for real people.

Alzheimer's Association@alzassociation.bsky.social · last mo.

Breaking News: Today, the U.S. Food and Drug Administration (FDA) cleared a fourth Alzheimer’s blood test for people experiencing signs or symptoms of cognitive impairment. This is the second blood-based biomarker test to be cleared in the past week. Read our statement: bit.ly/3SMm6KO.

Breaking News: Today, the U.S. Food and Drug Administration (FDA) cleared a fourth Alzheimer’s blood test for people experiencing signs or symptoms of cognitive impairment. This is the second blood-based biomarker test to be cleared in the past week. Read our statement: bit.ly/3SMm6KO.

Advances like this matter for people and families seeking answers. See below for our full statement.

Alzheimer's Association@alzassociation.bsky.social · last mo.

📰 Breaking News: The U.S. Food and Drug Administration (FDA) has cleared the third Alzheimer's blood test for individuals experiencing signs or symptoms of cognitive impairment. This is the first blood test cleared for use in patients as young as 40. Read our full statement: bit.ly/3TZ8fBg.

At #AAIC26 last week, we announced PROTECT-Cog to evaluate whether combining lifestyle intervention with a metabolism-targeting drug like a GLP-1 agonist can further reduce dementia risk. That’s a $100 million commitment – in science, progress, and people.

Alzheimer's Association@alzassociation.bsky.social · 3mo ago

📰 Today the Association announced the launch of the PROTECT-Cog Study to test U.S. POINTER lifestyle and GLP-1 or similar drug to cut risk of cognitive decline. Learn More: https://bit.ly/4pekZiJ

This LatAm-FINGERS news from #AAIC26 is big. Not just for science, but for the power of global scientific collaboration. www.thelancet.com/journals/lan...

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial

A culturally adapted multidomain lifestyle intervention was feasible across Latin America and resulted in greater cognitive improvements than a flexible health-advice intervention in older adults at r...

thelancet.com

Alzheimer's Association@alzassociation.bsky.social · 3mo ago

News from #AAIC26: Results from the Alzheimer's Association-funded LatAm-FINGERS study build on last year’s landmark findings from U.S. POINTER.

This reflects an important model of innovation — finding new ways existing drugs can help people living with Alzheimer's disease — and underscores the power of science to make an impact on people and families. See below for more on this new option for managing agitation in Alzheimer’s disease.

Alzheimer's Association@alzassociation.bsky.social · 5mo ago

Today, the FDA approved the first non-antipsychotic treatment for Alzheimer’s disease agitation — an important step forward for a symptom that is among the most challenging to manage in care. Read our statement >> bit.ly/3OBxY0l

Proud to announce new Part the Cloud investments: $11 million in 11 studies developing potential new treatments for Alzheimer’s and other diseases that cause dementia. This brings our total PTC investment to $90m+. More: bit.ly/3LtnYo1

Alzheimer's Association Part the Cloud Grants $11 Million to Develop Innovative Treatments

Grants were awarded to 11 studies developing innovative potential new treatments for Alzheimer’s and other diseases that cause dementia.

bit.ly

ISTAART is monitoring the potential impact of the government shutdown on researchers & the dementia care community where funds & staffing capacity are critical. Thanks to @alzassociation advocacy, NIH requested $187M increase in FY27. Bipartisan momentum in Congress is strong!

Proud to share the Alzheimer’s Association invested $112.2M in research activities over the last year — our largest single-year commitment. From gene therapy to #BrainHealth to risk reduction to AI, we’re funding bold boundary-pushing ideas. alz.org/research #ENDALZ

#AAIC2025 following USPointer recipe with a morning fun run!

Today’s news from #AAIC25 marks a moment so many of us in the Alzheimer’s and dementia scientific community have long hoped for. We can now say with confidence that lifestyle interventions can protect brain health in diverse communities in the U.S.

Alzheimer's Association@alzassociation.bsky.social · last yr.

📣Today is a turning point in what we know about brain health. The results from the U.S. POINTER trial provide the rigorous data needed to say with confidence that healthy behaviors can meaningfully protect brain health across diverse populations in the U.S. #AAIC25 alz.org/USPOINTERresults

📣Today is a turning point in what we know about brain health. The results from the U.S. POINTER trial provide the rigorous data needed to say with confidence that healthy behaviors can meaningfully protect brain health across diverse populations in the U.S. #AAIC25 alz.org/USPOINTERresults

“This is just the beginning,” @BillGates.bsky.social wrote in a new blog post. He’s right — Alzheimer’s and dementia research has more momentum than ever before, but now we need to go faster, earlier and bolder. That’s what @ALZAssocation’s Part the Cloud is all about.

Alzheimer's Association@alzassociation.bsky.social · last yr.

In a new blog post, @billgates.bsky.social shares his hope for—and commitment to—the fight to #ENDALZ, highlighting his support for the Association’s Part the Cloud initiative, which funds high-risk, high-reward clinical trials aimed at accelerating scientific breakthroughs. gatesnot.es/4edi98q

Congratulations to the recipients of the @alzassociation Part the Cloud Gene Targeting Challenge. This funding program is focused on gene editing, with the aim of developing potential therapies that change the expression of a gene at some level. bit.ly/4l8yEVx

Alzheimer's Association Part the Cloud Grants $5 Million to Develop Gene Targeting Treatments

Through the Alzheimer's Association, the Part the Cloud grants support development of innovative gene targeting treatments for Alzheimer's and dementia.

bit.ly

The myths and fabrications persistently shared by the Health and Human Services Secretary aren’t just disappointing – they’re dangerous. See below for the facts and for our full statement in response to the Secretary’s comments.

Alzheimer's Association@alzassociation.bsky.social · last yr.

❌ FALSE: “For 20 years…we were directing Alzheimer’s research to one hypothesis. And any other hypotheses were shut down.” - Sec. Kennedy Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)

It was a privilege to deliver one of the keynotes at today’s #CNDSymposium Day2 @iusm-medneuro.bsky.social alongside @elizabethhead.bsky.social @mariacarrilloalz.bsky.social. Congrats to @wilcocklab.bsky.social for the amazing 2 days of science 🤓💪🏼

@alzassociation.bsky.social CEO Dr Joanne Pike and the World Dementia Council rising chair is closing a fantastic day of discussions to accelerate innovation and deliver change! #ENDALZ

jamanetwork.com/journals/jam...

The Bad Medicine of Doctored

This Viewpoint discusses a recent book that alleges scientific misconduct in Alzheimer disease (AD) research; summarizes actual progress made in the field; suggests that the book contributes to a narr...

jamanetwork.com

📣 Join the "The Basics: Glymphatic System – A Focus on the Role of Sleep" @istaart.bsky.social webinar to learn the fundamental mechanisms of the glymphatic system and the critical role of #sleep in its function. 🧠🧼💤 📆 Register alz-org.zoom.us/webinar/regi... @claireandre.bsky.social #EndAlz

Observations from today’s confirmation hearing for the director of the NIH: 1. bipartisan support for addressing dementia was on full display & 2. harmful myths about Alzheimer’s research continue to persist and that needs to stop. Our full statement: bit.ly/4bql5Nv

Bipartisan Support for Alzheimer’s and Dementia Research During Senate HELP Committee

Read the Alzheimer's Association statement on the Senate HELP Committee hearing for the National Institutes of Health (NIH) director nominee.

bit.ly

So honored to be a part of this first symposium @IU @wilcocklab.bsky.social @malutansey.bsky.social to #ENDALZ

Dr. Donna Wilcock@wilcocklab.bsky.social · 2y ago

We encourage everyone who can to join us for the first annual Center for Neurodegenerative Disorders Symposium. Sunday April 13th for our community event and / or Monday April 14th for our scientific event. This is a free event and we have a virtual option! Scan the QR code to register!

Join us this week in San Juan #PuertoRico for Human Amyloid Imaging Conference #HAI2025 😊 Excited to participate in a panel discussion on disparities in neuroimaging & AD research, organized by the ISTAART Neuroimaging PIA and Diversity & Disparities PIA (Prof Interest Area)🤩

Love Languages GIF

ALT: Love Languages GIF

media.tenor.com

What an incredible time period to be working on updated appropriate use criteria for amyloid and tau PET! Awesome group to work with...I learned so much🧠 alz-journals.onlinelibrary.wiley.com/doi/10.1002/... @alzassociation.bsky.social @snm-mi.bsky.social

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

INTRODUCTION The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positro.....

alz-journals.onlinelibrary.wiley.com

🚨 ISTAART Voices is back! 🎉 Join us as we chat with scientists about their groundbreaking work from the Alzheimer’s & Dementia journal family. Tune in on your favorite podcast platforms, or visit alz.org/ISTAARTpodcasts! 🎧